Ask AI
Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies
Interactive Case Challenges: Atopic Dermatitis and IL-4/IL-13 and IL-13 Targeted Therapies

Released: April 30, 2025

Activity

Progress
1
Course Completed

Case Presentation 
Amy was prescribed a biologic agent targeting IL-13. During the next 16 weeks, her pruritus decreases significantly, her sleep improves, and she experiences a reduction in erythema and lichenification. 

During her follow-up visit at 16 weeks, she reports improvement of her symptoms, but she still experiences mild pruritus and occasional flares.

What additional measures should be considered to help Amy?